~ PRODUCTS ~

PILL PROTECT

Evaluates risks of thrombosis under contraceptive pills

Pill Protect® is an ingenious CE-IVD marked medical test that uses genetic and clinical data to identify women at risk of developing blood clots (thrombosis) when using contraceptive pills. It is the first clinically validated test and the best performing tool to identify women at risk of developing thrombosis under contraceptive pills.

More information

CYPASS & EXTENDED CYPASS

The genetic profiles that everybody should have

Cypass® and Extended Cypass® are innovative genetic tests that evaluate overall risk of adverse drug events. They integrate patient’s abilities to activate and eliminate drugs with drug-drug interactions simultaneously, thus allowing selecting for safer and more effective drug regimens that can improve drug treatment outcomes and reduce or avoid adverse drug reactions.

More information

NUTRIPASS

The test that allows matching nutrition to genes

Nutripass® is an exhaustive genetic and nutritional analysis that allows to tailor dietary habits and helps to optimize and improve health.

More information

~ GENETICS ~

HLA-B27

Genetic test assessing the risk of developing certain autoimmune disorders such as ankylosing spondylitis, reactive arthritis (Reiter’s Syndrome), psoriatic arthritis, ulcerative colitis associated spondyloarthritis, anterior uveitis and iritis.

LACTOSE

Analysis of the genetic variant leading to lactose intolerance.

GLUTEN

A classical undiagnosed problem. Look for genetic variants linked to gluten impaired metabolisation.

HOMOCYSTEINE

Analysis of genetic variants in MTHFR gene associated with high homocysteine levels.

HEMOCHROMATOSIS

Analysis of the genetic variants responsible for familial hemochromatosis, severe metabolic disease, that is often overlooked.

FACTOR II

Analysis looking for presence of absence of Factor II-G20210A genetic variant, associated with increased risk of developing deep-vein thrombosis and pulmonary embolism.

FACTOR V-LEIDEN

Analysis searching for the presence of absence of Factor V-Leiden genetic variant, associated with increased risk of developing deep-vein thrombosis and pulmonary embolism.